Windtree Therapeutics, Inc.
WINT
Windtree Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of acute cardiovascular and secondarily in acute pulmonary diseases. The company's lead development programs include istaroxime, which is in Phase IIb clinical trial for the treatment of acute decompensated heart failure, as well as in Phase IIa clinical trial for tā¦ read more
Healthcare
Biotechnology
30 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$0.02
Price0.00%
$0.00
1Y
Price
Market Cap
$674.176k
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow Margin-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow MarginRevenue
$90k
-
1y CAGR-
3y CAGR-
5y CAGREarnings
-$40.856m
-644.6%
1y CAGR-174.5%
3y CAGR-120.3%
5y CAGREPS
-$8.50
+91.9%
1y CAGR+93.7%
3y CAGR+83.9%
5y CAGRBook Value
-$11.610m
$15.983m
Assets$27.584m
Liabilities$12.928m
DebtDebt to Assets
80.9%
-1.1x
Debt to EBITDAFree Cash Flow
-$15.121m
+1.9%
1y CAGR+6.1%
3y CAGR+9.2%
5y CAGRNo items found.
Press Releases
Statements and updates from the company